Efficacy of Immune Checkpoint Inhibitors in Rare Tumours: A Systematic Review

Efficacy of Immune Checkpoint Inhibitors in Rare Tumours: A Systematic Review

BackgroundRare cancers, as defined by the European Union, occur in fewer than 15 out of 100,000 people each year. The International Rare Cancer Consortium defines rare cancer incidence as less than six per 100,000 per year. There is a growing number of reports of the efficacy of immune checkpoint in...

Full description

Bibliographic Details
Main Authors: Fausto Petrelli, Francesca Consoli, Antonio Ghidini, Gianluca Perego, Andrea Luciani, Paola Mercurio, Alfredo Berruti, Salvatore Grisanti
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Immunology
Subjects:
immunotherapy
rare tumours
systematic review
survival
anti-PD-(L)1 agents
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.720748/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.720748/full

Similar Items